Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to ...

In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...

Kenvue has a formidable lineup of well-known consumer health brands, such as Aveeno, Tylenol, Band-Aid, Zirtec, Listerine, ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

BofA raised the firm’s price target on Kenvue (KVUE) to $27 from $24 and keeps a Buy rating on the shares. Noting that The Wall Street ...

Kenvue shares jumped premarket after The Wall Street Journal reported that Starboard Value has taken a sizable stake in the ...

Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.

Shares of consumer-products company Kenvue Inc. rose the most in two months after the Wall Street Journal reported that ...

Starboard Values Investment in Kenvue Inc. Activist hedge fund Starboard Value has taken a sizeable stake in Kenvue Inc., ...